An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2016
At a glance
- Drugs GDC 0084 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 12 Mar 2016 Results assessing pharmacokinetics presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 19 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.